Evidence map›Paper›PMID 33977458›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2021

Strain Improvement Program of Streptomyces roseosporus for Daptomycin Production.

Sara Rubio, Sonia Martínez-Cámara, Juan Luis de la Fuente, Marta Rodríguez-Sáiz, José-Luis Barredo

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
4.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Discovery of a Novel Antimicrobial Peptide fromAntibiotics (Basel, Switzerland) · 2025
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sara RubioDepartment of Biotechnology, Crystal Pharma, A Subsidiary of Albany Molecular Research Inc. (AMRI), Parque Tecnológico de León, León, Spain.
Sonia Martínez-CámaraDepartment of Biotechnology, Crystal Pharma, A Subsidiary of Albany Molecular Research Inc. (AMRI), Parque Tecnológico de León, León, Spain.
Juan Luis de la FuenteDepartment of Biotechnology, Crystal Pharma, A Subsidiary of Albany Molecular Research Inc. (AMRI), Parque Tecnológico de León, León, Spain.
Marta Rodríguez-SáizDepartment of Biotechnology, Crystal Pharma, A Subsidiary of Albany Molecular Research Inc. (AMRI), Parque Tecnológico de León, León, Spain.
José-Luis BarredoDepartment of Biotechnology, Crystal Pharma, A Subsidiary of Albany Molecular Research Inc. (AMRI), Parque Tecnológico de León, León, Spain. joseluis.barredo@amriglobal.com.
Instituto Tecnológico de León · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Daptomycin is a cyclic lipopeptide antibiotic with potent activity against gram-positive bacteria. It has a calcium-dependent mechanism of action that disrupts multiple features of the bacterial membrane function. This antibiotic is highly demanded due to its effectiveness against to microorganisms resistant to other antibiotics, including vancomycin-resistant Staphylococcus aureus (VRSA) and methicillin-resistant S. aureus (MRSA). Daptomycin is produced by fermentation of Streptomyces roseosporus, currently identified as Streptomyces filamentosus. However, low fermentation yields and high production costs are reported. This chapter describes a method of strain improvement involving random mutagenesis, rational screening by bioassay, and flask fermentation. The ultimate objective is to select mutants of S. roseosporus overproducing daptomycin in order to design a more cost-effective daptomycin production.

Indexed as

Anti-Bacterial AgentsBacterial ProteinsDaptomycinFermentationGenetic EngineeringMethicillin-Resistant Staphylococcus aureusMutagenesisStreptomycesAnti-Bacterial AgentsBacterial ProteinsDaptomycinBioassayDaptomycinFermentationLipopeptide antibioticMutagenesisRational screeningStreptomyces filamentosusStreptomyces roseosporus

Identifiers

PMID33977458
OpenAlexW3160401932

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.